27 results about "Cysteine l" patented technology

This invention discloses a NK cell culture kit, its culture method, and its application. The kit includes an amplification medium, a high-efficiency induction medium, an NK-A coating solution, an NK-B mixture, and an NK-C mixture. The amplification medium contains basal medium, NAD+, human serum albumin, transferrin, β-glucan, glutathione, β-mercaptoethanol, and linoleic acid. The high-efficiency induction medium, in addition to the amplification medium components, contains soybean peptides, nicotinamide, inulin, and N-acetyl-L-cysteine. The NK-A coating solution contains heparin sodium, monoclonal antibodies, and antibodies. The NK-B mixture contains Inbakicept, IL-2, and IL-15. The NK-C mixture contains linolenic acid, IL-2, and IL-18. The Inbakicept factor in the kit can activate NK cells and enhance their cytotoxicity; linolenic acid can inhibit T cell proliferation, increase NK cell purity, and enhance cell efficacy.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

The application provides a preparation method of a composite water-retaining agent and application of the composite water-retaining agent in fermented meat products. The composite water-retaining agent is composed of a basic water-retaining agent and water-retaining microspheres. Components of the basic water-retaining agent include glutamine transaminase, trehalose, L-histidine and gellan gum, and the basic water-retaining agent plays a water-retaining role in a curing period; the water-retaining microspheres are prepared by embedding L-cysteine and reduced glutathione in Pediococcus pentosaceus fermented pineapple leaves as wall materials and vehiclepsin seed gum, and slowly release active substances under acid triggering in a late fermentation period, thereby playing a water-retaining role. The application provides a non-phosphorus composite water-retaining agent with better comprehensive performance than composite phosphate and commercial non-phosphorus water-retaining agents, significantly improves water-retaining property without interfering with fermentation, and provides a green, efficient and non-phosphorus special water-retaining solution for fermented meat products.

A composition for relieving hangovers and protecting the liver, made from the following raw materials in the indicated weight ratios: 3-20 parts of kudzu root extract, 2-20 parts of Japanese raisin tree fruit extract, 1-12 parts of N-acetylcysteine, 1-12 parts of L-ornithine, 1-15 parts of L-glutamine, 0.2-8 parts of glycyrrhetinic acid glycyrrhiza extract, 0.05-5 parts of curcumin, 0.005-0.5 parts of piperine, 0.5-10 parts of vitamin C, 0.01-2 parts of B vitamins complex, 0.1-8 parts of electrolyte salts, and 1-25 parts of honey or oligosaccharides.

Provided are gamma glutamylcysteine synthetase variants and microbial cells comprising such variants and / or expressing heterologous gamma-glutamylcysteine synthetase-glutathione synthetases, for producing increased amounts of the antioxidant peptide glutathione (GSH). Methods and compositions provided herein may be useful in baking and winemaking applications and in production of nutraceuticals, pharmaceuticals, cosmetics, plant protectants and / or animal feeds.

Use of hair treatment compositions comprising anionic surfactants, amphoteric surfactants, nonionic surfactants, amphoteric surfactants, cationic surfactants, or combinations thereof, for repairing damage to hair proteins in hair; amino acid complexes containing glutamic acid, serine, glycine, cysteine, and histidine; and fiber-activating complexes.

The application provides application of a reagent for detecting N-acetyl-L-cysteine in preparation of an ischemic brain injury diagnosis product, and relates to the technical field of in-vitro detection.The application provides a biomarker N-acetyl-L-cysteine (NAC) for ischemic brain injury diagnosis.ROC curve analysis shows that NAC has good distinguishing ability for ischemic brain injury, and can be used as a potential marker for ischemic brain injury.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

The application belongs to the technical field of biotechnology, and particularly relates to a staged precise regulation in vitro expansion culture method of high-activity gamma delta T cells. In the synergistic activation stage, the complex activator containing zoledronic acid, IL-2, IL-15, IL-12 and IL-21 is used to significantly improve the early activation level of the gamma delta T cells; in the dynamic expansion stage, the concentration of metformin is adjusted step by step to support the continuous and efficient proliferation of the cells; in the gradient maturation stage, the combination system of N-acetyl cysteine, TWS119 and DL-alpha tocopheryl acetate is introduced to help maintain the functional activity and antioxidant state of the cells in the later culture stage. The gamma delta T cells with a purity higher than 90% and an expansion multiple more than 100 times can be obtained by using the method to culture for 10 days, and the cells exhibit significant killing activity to tumor cells, are suitable for the adoptive immunotherapy of tumor and infectious diseases, and have good clinical application prospects.

The application provides a lung organ culture medium and application thereof, and particularly, the culture medium comprises a basic culture medium, G27, hEGF, a BMP inhibitor, a ROCK inhibitor, L-glutamine, HEPES, an antibiotic, and at least one selected from the group consisting of nicotinamide, a Wnt agonist, N-acetylcysteine and a TGF-beta inhibitor. The lung organ and the virus infection model thereof cultured by the culture medium are a good-repeatability and standardized infection model, can fully simulate the virus infection condition of a natural virus host, and are suitable for research on a virus pathogenesis, high-throughput screening of antiviral drugs, toxicity evaluation and drug research and development.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

The application discloses a culture medium for constructing a liver cancer lung metastasis microtumor model and application thereof. The application relates to the technical field of biology, and provides a culture medium for constructing a liver cancer lung metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant proteins EGF, HGF, IL-2, IL-15, R-spondin1, CXCL12, recombinant human lung surfactant proteins SP-A, SP-D, forskolin, A83-01, N-acetyl-L-cysteine, nicotinamide, N2 additives, B27 and a basic culture medium. The culture success rate of the liver cancer lung metastasis microtumor model is effectively improved.

Methods for increasing reelin (RELN) levels in the brain of a subject in need thereof, as well as compositions for use in such methods, are provided. In addition, methods and compositions are described herein which may be used in the treatment of neuropsychiatric or neurodegenerative disorders, such as schizophrenia and Alzheimer's disease (AD). Compositions described herein may comprise whey protein isolate and / or whey protein concentrate, a source of the glutathione precursor cysteine. The provided methods and compositions are not limited to increasing RELN levels, and may be used to correct a number of other neurological disregulations or abnormalities occurring in a subject in need thereof.

The application discloses an ex vivo perfusion preservative solution for improving the curative effect of liver transplantation. 1000 mL of the ex vivo perfusion preservative solution comprises the following components: 20-60 mg of oxamic acid, 2 g of sodium penicillin, 15000-20000 U of heparin, 20 mg of N-acetyl cysteine, and HTK liquid is supplemented to 1000 mL. The ex vivo perfusion preservative solution for improving the curative effect of normal liver and fatty degeneration liver transplantation can effectively improve the liver injury caused by I / R. Compared with the HTK liquid used at present, the ex vivo perfusion preservative solution has better protection effect, and has a good application prospect for the preservation of donor liver in liver transplantation surgery, especially the fatty degeneration liver.

This invention discloses a high-glutathione-producing engineered Escherichia coli strain and its applications, belonging to the field of biotechnology; the engineered Escherichia coli strain is named ZMGSH01F, with accession number CCTCC M 20252236; the engineered Escherichia coli strain is based on Escherichia coli BL21(DE3) as the starting strain, with gene clusters knocked out. ptsH‐ ptsI‐crr And integrate at this site glf‐glk Fusion genes, knockout gene clusters gsiA‐gsiB‐gsiC Integrate the endogenous glutathione transporter gene at this site. cycDC Knockout of γ-glutamyltransferase gene ggt Simultaneously expressing the recombinant plasmid pRSFDuet- gshAB K177E‑E275K‑V513A - ppk2 The engineered Escherichia coli strain can efficiently produce glutathione through fermentation culture using glucose, monosodium glutamate, cysteine, and glycine as substrates.

This invention belongs to the field of biomedical technology, specifically relating to the application of metabolic markers in the preparation of products for diagnosing abdominal aortic aneurysms. The metabolic markers include 5-δ-hydroxybutylhydantoin, 1-α-amino acid, and PGF. 2α The present invention provides one or more of the following metabolites: D-pyroglutamic acid, nicotinic glucuronide, cysteine ​​glutathione disulfide, or Trp-P-1. Experiments have confirmed that the seven metabolites, alone or in combination, have good specificity and sensitivity as metabolic markers for diagnosing abdominal aortic aneurysms.

The application discloses a kind of composite fluorescent visualization sensor and its preparation method and application, it is related to analytical detection technical field;Composite fluorescent visualization sensor is prepared by the following method: first, synthesis of sulfhydryl succinic acid modified cadmium telluride quantum dots and N-acetyl-L-cysteine modified cadmium telluride quantum dots, then porphyrin stock solution is mixed with N-acetyl-L-cysteine modified cadmium telluride quantum dots, namely the chiral nano porphyrin solution can be obtained, finally it is mixed with the sulfhydryl succinic acid modified cadmium telluride quantum dots synthesized in advance, and composite fluorescent visualization sensor can be prepared;The composite fluorescent visualization sensor of quantum dot-nano porphyrin prepared by the application has good selectivity to L / D- theanine and has high sensitivity and anti-interference performance, and can be used for visualizing precise analysis of L / D- theanine content, with the advantages of simple operation, high sensitivity, low cost and the like.

The application relates to the technical field of medicines, and particularly discloses a novel immune stimulant, a preparation method and application thereof. The immune stimulant comprises an alpha-mannose modified imidazoquinoline derivative, an N-acetyl cysteine modified cytosine-guanine dinucleotide, a glycyrrhetinic acid-polyethylene glycol derivative, a phytic acid-glycine oligomer, a medicinal excipient and water for injection, three modified active ingredients are bridged by the phytic acid-glycine oligomer as a bridging unit, and a ternary coordination complex is formed through dynamic non-covalent coordination. The preparation method comprises the following steps: after raw materials are pretreated, the active ingredients are premixed, dissolved and solvent is recovered, then dynamic coordination reaction, ultrafiltration purification and concentration are carried out, and finally, a finished product is obtained through double-cavity preparation forming. The immune stimulant can be used for preparing a tumor immunotherapy, an anti-infection treatment, an immune deficiency disease auxiliary treatment drug or a vaccine adjuvant, and has the advantages of high active ingredient stability, good in-vivo delivery efficiency and outstanding synergistic effect.

Provided herein are perfusate compositions, and methods and systems for using such composition to perfuse a vascularized composite tissue (e.g., limb, face, abdominal wall or flap) to preserve such composite tissues (e.g., for auto or allotransplant). In certain embodiments, the perfusate compositions comprise at least one of the following reagents: i) N-acetylcysteine; ii) pantothenate or pantothenic acid at a concentration of at least 15 micromol / liter in said composition; and / or iii) carnitine, as well as further comprising one of the following: i) at least one bicarbonate / CO2-dependent anaplerotic substrate, and at least one bicarbonate / CO2 buffer, or ii) at least one non-bicarbonate / CO2-dependent anaplerotic substrate. In certain embodiments, the perfusate compositions are free, or detectably free, of alpha amino acids.

This invention discloses a method for immobilizing an enzyme with a zeolite imidazole ester skeleton and its application in the synthesis of L-glutathione (GSH). The aim is to provide an immobilized enzyme that effectively improves enzyme stability and reusability, characterized by simple operation and mild conditions. The technical solution involves adding purified glutathione bifunctional enzyme (GshF) and an aqueous solution of 2-methylimidazole to a Zn(NO3)2 solution. After stirring for a certain period, the product is collected by centrifugation, washed, and dried to obtain the immobilized enzyme (GshF@ZIF-L). This catalyst is then used to catalyze the synthesis of L-glutathione from glutamic acid, cysteine, and glycine. This invention offers advantages such as simple operation, high encapsulation efficiency, good catalytic stability, and recyclability. It can be used for the green biocatalytic preparation of reduced glutathione and has great application potential in the fields of medicine, food, and cosmetics.

The application relates to the fields of biological medicine and high polymer materials, and discloses a sustained-release implant type biodegradable stent loaded with an antitumor active component, which is composed of polylactic acid-glycolic acid copolymer, doxorubicin hydrochloride, citric acid-terminated polyethylene glycol polymer, zinc acetate dihydrate and N-acetyl cysteine. The metastable complex structure is constructed by in-situ coordination reaction between the components, so that the rapid release of the water-soluble doxorubicin hydrochloride in the initial implantation stage is blocked. After implantation, N-acetyl cysteine is preferentially dissociated and released, so that the zinc ion coordination unsaturated sites are generated in the coordination network; with the hydrolysis of the polylactic acid-glycolic acid copolymer, the generated lactic acid molecules intervene in the above unsaturated sites to generate a competitive coordination reaction, so that the coordination skeleton is destroyed and the antitumor drug is released. The application realizes the synchronization of the drug release rate and the high polymer matrix degradation rate, and the acetate dissociated from the zinc acetate can effectively buffer the pH value of the degradation microenvironment.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

Provided herein are methods for the treatment of retinitis pigmentosa in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA).

Provided herein is a method of decomposing polystyrene waste and a method of enhancing the decomposition of polystyrene waste by Mealworms using certain amino acids. The method comprises treating Mealworms or polystyrene waste with free amino acids before or at the same time as the decomposition of polystyrene waste using Mealworms. The free amino acids are selected from essential amino acids and non-essential amino acids, the essential amino acids being selected from phenylalanine, tryptophan, valine; the non-essential amino acids being selected from cysteine, glutamine and glutamic acid.

The present disclosure generally relates to compositions and methods that can treat or prevent nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatitis and / or hepatic steatosis (fatty liver). More specifically, the present disclosure relates to administering a formulation comprising a combination of at least one glycine or functional derivative thereof, and / or at least one N-acetylcysteine or functional derivative thereof, and at least one thymol and / or carvacrol, in an amount effective to decrease liver steatosis. The formulation can concomitantly decrease liver damages, in particular those observed in patients with NAFLD.

The application discloses a kind of pharmaceutical composition for treating liver injury of acetylaminophenol permeation and application, belong to biological medicine field.The composition is composed of N-acetylcysteine or its pharmaceutically acceptable salt, 8-oxo guanine DNA glycosylase 1 specific activator, preferably the activator is TH10785 and its derivative, synergistic effect of both.The composition can break through the traditional 8 hours treatment window of NAC, realize late intervention in poisoning, play the efficacy by repairing DNA oxidative damage, inhibiting Z-DNA generation, blocking ZBP1 path, inhibiting hepatocyte pyroptosis and liver inflammation.Drug can be made into various dosage forms, and matched special treatment kit.The application prolongs clinical treatment time, and double target points synergistically improve treatment effect, target point is novel, applicability is strong, with good clinical transformation prospect.

A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.